Posted inClinical Updates Gastroenterology
Elafibranor as an Effective Second-Line Treatment to Normalize Alkaline Phosphatase in Primary Biliary Cholangitis with Incomplete Response to Ursodeoxycholic Acid: Synthesizing Evidence from the Phase III ELSPIRE Trial and Related Studies
Elafibranor demonstrates significant efficacy and safety in normalizing alkaline phosphatase among PBC patients inadequately responding to UDCA, establishing ALP normalization as a treatment goal and supporting its role as a second-line therapeutic option.